Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation
about
Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pathological complete response ...... edicted by HSD17B4 methylation
@en
Pathological complete response ...... dicted by HSD17B4 methylation.
@nl
type
label
Pathological complete response ...... edicted by HSD17B4 methylation
@en
Pathological complete response ...... dicted by HSD17B4 methylation.
@nl
prefLabel
Pathological complete response ...... edicted by HSD17B4 methylation
@en
Pathological complete response ...... dicted by HSD17B4 methylation.
@nl
P2093
P2860
P356
P1433
P1476
Pathological complete response ...... edicted by HSD17B4 methylation
@en
P2093
Hirofumi Mukai
Masato Takahashi
Satoshi Fujii
Satoshi Yamashita
Takeshi Yamaguchi
Yasuo Hozumi
P2860
P304
19039-19048
P356
10.18632/ONCOTARGET.15118
P407
P577
2017-02-06T00:00:00Z